Diagnostics industry companies, patient groups, [BB1]and trade associations are speaking up in the wake of last week’s news that US Food and Drug Administration user fee reauthorization legislation – which Congress must pass soon to maintain agency operations – might not include long-discussed diagnostic regulatory reforms.
The VALID (Verifying Accurate Leading-edge IVCT Development) Act, which would allow the FDA to regulate in vitro diagnostics, including lab-developed...